Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/760965 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566897572315136 |
|---|---|
| author | Kyle K. Payne Amir A. Toor Xiang-Yang Wang Masoud H. Manjili |
| author_facet | Kyle K. Payne Amir A. Toor Xiang-Yang Wang Masoud H. Manjili |
| author_sort | Kyle K. Payne |
| collection | DOAJ |
| description | The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs) can generate robust antitumor immune responses, which implicates CTAs as potential targets for immunotherapy. However, the heterogeneity of tumor cells in the presence and quantity of CTA expression results in tumor escape from CTA-specific immune responses. Thus, the ability to modulate the tumor cell epigenome to homogenously induce expression of such antigens will likely render the tumor more immunogenic. Additionally, emerging studies suggest that suppression of antitumor immune responses may be overcome by reprogramming innate and adaptive immune cells. Therefore, this paper discusses recent studies which address barriers to successful cancer immunotherapy and proposes a strategy of modulation of tumor-immune cell crosstalk to improve responses in carcinoma patients. |
| format | Article |
| id | doaj-art-634837ec7edd474ba5cfe3d50a6de7da |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-634837ec7edd474ba5cfe3d50a6de7da2025-02-03T01:02:48ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/760965760965Immunotherapy of Cancer: Reprogramming Tumor-Immune CrosstalkKyle K. Payne0Amir A. Toor1Xiang-Yang Wang2Masoud H. Manjili3Department of Microbiology & Immunology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USADepartment of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USADepartment of Human and Molecular Genetics, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USADepartment of Microbiology & Immunology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USAThe advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs) can generate robust antitumor immune responses, which implicates CTAs as potential targets for immunotherapy. However, the heterogeneity of tumor cells in the presence and quantity of CTA expression results in tumor escape from CTA-specific immune responses. Thus, the ability to modulate the tumor cell epigenome to homogenously induce expression of such antigens will likely render the tumor more immunogenic. Additionally, emerging studies suggest that suppression of antitumor immune responses may be overcome by reprogramming innate and adaptive immune cells. Therefore, this paper discusses recent studies which address barriers to successful cancer immunotherapy and proposes a strategy of modulation of tumor-immune cell crosstalk to improve responses in carcinoma patients.http://dx.doi.org/10.1155/2012/760965 |
| spellingShingle | Kyle K. Payne Amir A. Toor Xiang-Yang Wang Masoud H. Manjili Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk Clinical and Developmental Immunology |
| title | Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk |
| title_full | Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk |
| title_fullStr | Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk |
| title_full_unstemmed | Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk |
| title_short | Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk |
| title_sort | immunotherapy of cancer reprogramming tumor immune crosstalk |
| url | http://dx.doi.org/10.1155/2012/760965 |
| work_keys_str_mv | AT kylekpayne immunotherapyofcancerreprogrammingtumorimmunecrosstalk AT amiratoor immunotherapyofcancerreprogrammingtumorimmunecrosstalk AT xiangyangwang immunotherapyofcancerreprogrammingtumorimmunecrosstalk AT masoudhmanjili immunotherapyofcancerreprogrammingtumorimmunecrosstalk |